Loading…
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $139M | $-91M | $-107M | $-80M | -36.2% | 2.4% | - |
| 2024 | $135M | $-44M | $-39M | $-39M | -11.7% | 11.8% | - |
| 2023 | $121M | $-36M | $-28M | $-23M | -8.1% | 15.4% | - |
| 2022 | $105M | $-69M | $-100M | $-60M | -27.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 104.95 | 121.14 | 135.44 | 138.65 |
| Cost Of Revenue | 60.16 | 48.14 | 54.32 | 73.94 |
| Gross Profit | 44.79 | 73 | 81.12 | 64.72 |
| Operating Expense | 119.50 | 117.66 | 133.74 | 174.53 |
| Operating Income | -74.71 | -44.66 | -52.62 | -109.81 |
| EBITDA | -68.58 | -36.37 | -44.26 | -90.89 |
| EBIT | -74.71 | -44.66 | -52.62 | -109.81 |
| Pretax Income | -99.41 | -27.64 | -38.10 | -112.27 |
| Tax Provision | 0.16 | 0.72 | 0.43 | -5.12 |
| Net Income | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income Common Stockholders | -99.57 | -28.35 | -38.53 | -107.15 |
| Total Expenses | 179.66 | 165.80 | 188.05 | 248.47 |
| Interest Income | 5.13 | 15.84 | 14.65 | 8.57 |
| Research And Development | 26.81 | 26.06 | 31.08 | 35.92 |
| Selling General And Administration | 93.26 | 92.82 | 104.64 | 138.85 |
| Normalized EBITDA | -39.03 | -35.05 | -44.26 | -79.71 |
| Normalized Income | -76.22 | -27.30 | -38.53 | -96.48 |
| Basic EPS | -2.61 | -0.75 | -1 | 0 |
| Diluted EPS | -2.61 | -0.75 | -1 | 0 |
| Tax Effect Of Unusual Items | -6.21 | -0.28 | 0 | -0.51 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.05 |
| Total Unusual Items | -29.56 | -1.33 | 0 | -11.18 |
| Total Unusual Items Excluding Goodwill | -29.56 | -1.33 | 0 | -11.18 |
| Net Income From Continuing Operation Net Minority Interest | -99.57 | -28.35 | -38.53 | -107.15 |
| Reconciled Depreciation | 6.12 | 8.29 | 8.36 | 18.93 |
| Reconciled Cost Of Revenue | 60.16 | 48.14 | 54.32 | 73.94 |
| Net Interest Income | 5.13 | 15.84 | 14.65 | 8.57 |
| Net Income From Continuing And Discontinued Operation | -99.57 | -28.35 | -38.53 | -107.15 |
| Rent Expense Supplemental | 1.41 | 3.71 | 3.02 | 0.84 |
| Total Operating Income As Reported | -104.26 | -45.99 | -52.62 | -125.54 |
| Diluted Average Shares | 36.99 | 37.59 | 38.37 | 0 |
| Basic Average Shares | 36.99 | 37.59 | 38.37 | 0 |
| Diluted NI Availto Com Stockholders | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income Including Noncontrolling Interests | -99.57 | -28.35 | -38.53 | -107.15 |
| Net Income Continuous Operations | -99.57 | -28.35 | -38.53 | -107.15 |
| Other Income Expense | -29.83 | 1.19 | -0.14 | -11.02 |
| Other Non Operating Income Expenses | -0.28 | 2.52 | -0.14 | 0.16 |
| Special Income Charges | -29.56 | -1.33 | 0 | -11.18 |
| Impairment Of Capital Assets | 29.56 | 1.33 | 0 | 15.73 |
| Restructuring And Mergern Acquisition | 3.75 | 0 | 0 | -4.55 |
| Net Non Operating Interest Income Expense | 5.13 | 15.84 | 14.65 | 8.57 |
| Total Other Finance Cost | -5.13 | -15.84 | 0 | 0 |
| Interest Income Non Operating | 5.13 | 15.84 | 14.65 | 8.57 |
| Other Operating Expenses | -0.57 | -1.23 | -1.99 | -0.24 |
| Selling And Marketing Expense | 92 | 0 | 0 | 0 |
| General And Administrative Expense | 93.26 | 92.82 | 104.64 | 138.85 |
| Other Gand A | 91.85 | 89.11 | 101.62 | 138.01 |
| Rent And Landing Fees | 1.41 | 3.71 | 3.02 | 0.84 |
| Operating Revenue | 104.95 | 121.14 | 135.44 | 138.65 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Quanterix Corporationthis co. | QTRX | $144M | - | 0.48 | -36.2% | -0.86 |
| Journey Medical Corporation | DERM | $166M | - | 4.26 | -35.9% | -35.25 |
| Anika Therapeutics, Inc. | ANIK | $165M | - | 1.20 | -7.6% | -31.67 |
| Pro-Dex, Inc. | PDEX | $160M | 14.62 | 3.84 | 24.5% | 12.89 |
| Fate Therapeutics, Inc. | FATE | $144M | - |
| 0.69 |
| -65.8% |
| -0.14 |
| SANUWAVE Health, Inc. | SNWV | $143M | 40.51 | 88.35 | 729.6% | 20.54 |
| TuHURA Biosciences, Inc. | HURA | $134M | - | 6.03 | -143.6% | -4.67 |
| AVITA Medical, Inc. | RCEL | $130M | - | -7.76 | 291.8% | -3.91 |
| The Joint Corp. | JYNT | $127M | - | 8.33 | 19.3% | 140.09 |
| Peer Median | - | 27.56 | 4.05 | 5.8% | -2.02 | |